|
CYP20A1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.77395900588817E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.01900734914307E-14 |
| Normal-vs-Stage2 |
4.99644770002305E-12 |
| Normal-vs-Stage3 |
3.33066907387547E-16 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
9.269600E-01 |
| Stage1-vs-Stage3 |
2.970100E-02 |
| Stage1-vs-Stage4 |
3.69559999999769E-05 |
| Stage2-vs-Stage3 |
1.196780E-01 |
| Stage2-vs-Stage4 |
3.176000E-03 |
| Stage3-vs-Stage4 |
6.919900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62592161956354E-12 |
| Normal-vs-AfricanAmerican |
1.37619999951433E-07 |
| Normal-vs-Asian |
2.33146835171283E-15 |
| Caucasian-vs-AfricanAmerican |
2.888200E-01 |
| Caucasian-vs-Asian |
8.183000E-01 |
| AfricanAmerican-vs-Asian |
3.387800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.63635771599502E-12 |
| Normal-vs-Female |
4.21884749357559E-15 |
| Male-vs-Female |
8.147200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.20614670765463E-14 |
| Normal-vs-Age(41-60Yrs) |
1.62492241884138E-12 |
| Normal-vs-Age(61-80Yrs) |
9.76996261670138E-15 |
| Normal-vs-Age(81-100Yrs) |
4.615500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.429900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.248400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.815200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.962800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.713800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.244000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.558880E-04 |
| Classical-VS-Follicular |
1.320750E-01 |
| Classical-VS-Other |
4.446400E-01 |
| Classical-VS-Normal |
4.00790511889682E-14 |
| Tall-VS-Follicular |
3.67199999999901E-05 |
| Tall-VS-Other |
2.925000E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
2.784400E-01 |
| Follicular-VS-Normal |
2.1870283362091E-12 |
| Other-VS-Normal |
7.82920000000908E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.25215418431435E-14 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
8.393800E-04 |
|
|
